Sagiment Biosciences Inc (SGMT) Opciones

hope to see a new high

now the oppenheimer 30$ ! target
has weight vs the Wedbush Wainwright pumps.... Good stuff happening here
maybe out of the sand trap

Viking Wins First Round In Legal Battle With Ascletis (sagimet partner in China whats really strange ts the CEO Jinzi Jason Wu was on the board of directors on SGMT a few months ago maybe this is why they are having issues getting a deal the company might be blacklisted in the pharma industry. Gannex’s patent applications related to the compound. Wu is listed as an inventor on these patents.( was really interesting is Sagimet was 3-V Biosciences, before the spin out merger
Both Firms Pursuing MASH Candidates
https://insights.citeline.com/SC151011/Viking-Wins-First-Round-In-Legal-Battle-With-Ascletis-Over-THR-Agonist/

Viking Therapeutics accuses Chinese co of stealing fatty liver disease drug secrets
Viking Therapeutics accuses competitor of pilfering proprietary ...
Chemical & Engineering News
https://cen.acs.org › drug-development › web › 2023/01
Jan 9, 2023 — Viking Therapeutics has sued a group of companies, as well as their common founder and CEO, Jinzi Jason Wu, for allegedly stealing the trade secrets of a ...



Nevertheless, in 2019, Ascletis BioScience approached Viking again to propose another pact involving the same molecule. Under a similar confidentiality agreement, Ascletis perused Viking’s electronic files, but over a month into their review, Ascletis backed out of the partnership opportunity.

It was all “a ruse to steal Viking’s VK2809 trade secrets,” the complaint claims. Five months after the second meeting, Wu founded Gannex Pharma to develop a rival liver-disease drug. The lawsuit purports that Viking discovered the theft after the 2021 publication of Gannex’s patent applications related to the compound. Wu is listed as an inventor on these patents.


Gannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.


Rug pull or can the CFO pull a rabbit out of his hat CEO Happel seems overwhelmed not a good pick to run SGMT.

The hair falling out on the phase 2B Mash trial for SGMT is also a concern for patients and potential partners.
some patients “experienced hair thinning"


$SGMT

I would be shocked if the CFO did an offering at these levels.

I think partnership or buyout with Madrigal is in the works.

Core Holding!

$SGMT

Looking good here. Keep in mind offering was done at 12.50 strike in January via Goldman. Great NASH science... liver fat synthesis oral administrationi
https://www.globenewswire.com/news-release/2024/01/26/2817557/0/en/Sagimet-Biosciences-Announces-Pricing-of-Public-Offering-of-Series-A-Common-Stock.html

21 m float $5.12 + 14%

We are just getting started I pounded the table to load up in the mid 2's low 3's
LFG!
$SGMT

Fortunes to be made with the ones who have balls of fortitude buy the fear and make the big money !

$SGMT

LFG. Happy Friday!

$SGMT

Loaded to the Gills!

Will wait for the buyout at 1-2 Billion by 2027

$SGMT

want one more chunk of shares under $4.00 this week!

$SGMT

Reached 300K shares Long! Blessed

$SGMT

Another 20k at $4.00 added already this morning thank you! bless!

$SGMT

adding more today!

$SMGT

Added 18k end of the day under $4.00 up to 257k shares Largest Holding after today!

$SGMT

Thierry Chauche - New CFO SGMT 2024

Thierry Chauche :
Vice President, Head of Strategic FP&A at Alexion Pharmaceuticals, Inc.


$39 billion
In the largest pharmaceutical deal of the year, British pharmaceutical giant AstraZeneca has acquired American biotech firm and rare diseases specialist Alexion for $39 billion.

The total consideration paid to the Alexion shareholders was approximately $13.3bn in cash and 236,321,411 new AstraZeneca shares (approximately 94% of which will be represented by new AstraZeneca American Depositary Shares (ADSs)).

Provention Bio Announces Appointment of Thierry Chauche as Chief Financial Officer:
Provention Bio in its $2.9 billion acquisition by Sanofi, among other achievements.

Whats even more interesting is that SGMT believes that as the trials continue they will show better efficacy than AKRO which is a IV infusion with a market cap of 2 Billion SGMT drug is three times more effective than MDGL drug hence the https://ir.sagimet.com/news-releases/news-release-details/sagimet-receives-fda-breakthrough-therapy-designation

Another catalyst is Phase 2 MASH in Pediatric look to start Phase 2 in 2025
SGMT drugDenifanstat Combo Data with GLP1 and THR Betas knock it out of the park.
https://sagimet.com/posterspublications/

It Looks like the new CFO came in to negotiate a buyout there are big hitters on the board of Directors including Tim Walbert:
Mr. Walbert has nearly 30 years of biotechnology and industry experience. He joins Sagimet’s board following a 15-year tenure as president, chief executive officer, and chairman of the board at Horizon Therapeutics, which he built from inception to a leading rare disease company. In 2023, Amgen acquired Horizon for $28 billion, and Mr. Walbert currently serves as a senior advisor to Amgen.


Paul Hoelscher

Mr. Hoelscher served as executive vice president and chief financial officer of Horizon Therapeutics from 2014 to 2022, prior to the company’s acquisition by Amgen. Prior to joining Horizon, Mr. Hoelscher held multiple financial executive roles in various consumer products, retail and business services companies, as well as working in the audit practice of KPMG LLP.

The previous CMO of GIlead who just retired from Gilead a few months ago is also on the board:

Merdad Parsey, MD, PhD

Dr. Parsey joined Sagimet Biosciences as president, chief executive officer and board director in September 2010 and stepped down from the role of president and chief executive officer in 2015. He is currently Chief Medical Officer at Gilead Sciences, Inc. Previously, Dr. Parsey held positions at Genentech, Inc., a member of the Roche Group, Sepracor, Regeneron and Merck, Inc. He has worked on multiple development and post-marketing programs from initial human trials to NDA/BLA submissions in respiratory, inflammation, virology, neurology, ophthalmology and gastrointestinal diseases.

Looks like MDGL GILD AMGN NVO LLY could be potential suitors the magnitude of this oral molecule is a next level blockbuster for a variety of big indications>

https://sagimet.com/about/board-of-directors/

https://sagimet.com/about/executives/

AKRO 2 Billion market cap
ETNB 720 Million market cap
SGMT 130 Million market cap with a versatile fat syntheizer molecule that can treat a variety of diseases including a wide array of oncology indications.

Nearly 60 Million shares traded last week A buyout is in the works that why thierry chauche was brought on as the CFO for SGMT this year.


An example of AKRO history:
$SGMT We reached step #3

Akero:
#1 - Sep 13, 2022 Efruxifermin phase 2b results
#2 - Sep 14, 2022 - offering
#3 - Dec 8 2022 - Efruxifermin Granted FDA Breakthrough Therapy Designation
#4 - Mar 29, 2023 - Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program
#5 - May 16, 2023 - one more offering
#6 - Dec 18, 2023 - Phase 3 - first patient dosed.

Second example is ETNB 89 Bio:
$SGMT Similar sequence of steps, but for 89Bio


#1 - Mar 22 2023 - pegozafermin phase 2b results
#2 - Mar 22 2023 - offering
#3 - Sep 21 2023 - FDA has Granted Breakthrough Therapy Designation to pegozafermin
#4 - Dec 04 2023 - Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)
#5 - Dec 12 2023 - one more offering
#6 - Mar 12 2024 - phase 3 first patient dozed

In this case either a buyout a partnership should happen sooner than later with catalyst of completion of FDA meeting on Phase 3 design complete and start of Phase 3

Price Target

The average one-year price target for Sagimet Biosciences Inc. is $33.25. The forecasts range from a low of $6.06 to a high of $70.35
When Goldman Lowered their PT on SGMT is when I started accumulating shares!

$SGMT

This is just the beginning. $10+ before the end of the year.

Pump it 3.60s

Presentation Tomorrow

Big move today, but I don’t see any news. Anyone know what’s going on?

SGMT under $4

Anyone know why this has been tanking so bad the last couple weeks?

SGMT under $5

Sagimet Biosciences (Nasdaq: SGMT $6.25)
Buy recommendation.

Market cap = $199M
Cash = $210M+ (Just raised $112M through a secondary offering)
Estimated cash burn = ($25)/year
Lead product = Denifanstat an oral, once daily pill and selective first-in-class FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).
Jan. 22, 2024 announced positive topline results from Phase 2b clinical trial of Denifanstat in Biopsy-confirmed F2/FS NASH.
The results are comparable to Madrigal's Resmitiron.
Ascletis collaboration agreement = Potential $122M in milestone payments as well as tiered royalties ranging from percentages in the high single digits to mid-teens on future net sales of Denifanstat, which is referred to as ASC40 in Greater China
Most AEs (adverse events) were Grade 1 or 2 (mild to moderate). There were no Grade 3 AEs.

See if $10 level holds. MC could drift upward later this year towards $1B area as company is similar to ETNB…

Yup, got out at 16.25, thought they had enough in the coffers to push through this year. It was a good score while it lasted.

Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock
https://newsfilter.io/articles/sagimet-biosciences-announces-pricing-of-public-offering-of-series-a-common-stock-c3511595df124183e48b41923f34e655

Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock
https://ir.sagimet.com/news-releases/news-release-details/sagimet-biosciences-announces-proposed-public-offering-series

congrats!

Only down 5% for after hours. Nothing to sweat over.

Three nice winners in my circle.

Looks like another run tomorrow.

that was fun! i love “bar charts as…

…

” i get a lot of good leads from that free website.

hey dino, looks like we got a runner here, weeeee!!

grabbed a few on the dip. hi all.

Looks like easy 500% gainer today.

What a great move and Baker Brothers in it, I simply got lucky at 11.38 with 2500 shares. Looks like billion dollar market cap is going to fetched here real soon.

That 20k block they filled at 9.69 before ripping

Yummy

Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH